Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Bertilsson

Showing results (151-160 of 263) with videos related to

Pageof 27
Sort By:
Pharmacology & Toxicology|February 1, 1991
Stereoselective efflux of (E)-10-hydroxynortriptyline enantiomers from the cerebrospinal fluid of depressed patientsL Bertilsson, K Otani, M L Dahl, et al.
Biological Psychiatry|September 24, 1999
Locus coeruleus neuronal activity and noradrenaline availability in the frontal cortex of rats chronically treated with imipramine: effect of alpha 2-adrenoceptor blockadeL Linnér, L Arborelius, G G Nomikos, et al.
Therapeutic Drug Monitoring|May 22, 2001
Determination of exogenous melatonin and its 6-hydroxy metabolite in human plasma by liquid chromatography-mass spectrometryS Härtter, S Morita, K Bodin, et al.
Archives of General Psychiatry|July 1, 1980
Cortisol in the CSF of depressed and suicidal patientsL Träskman, G Tybring, M Asberg, et al.
Therapeutic Drug Monitoring|January 1, 1988
Single-dose kinetics of an enteric-coated formulation of carbamazepine-10,11-epoxide, an active metabolite of carbamazepineE Spina, T Tomson, J O Svensson, et al.
British Journal of Clinical Pharmacology|May 1, 1988
Effect of valpromide on the pharmacokinetics of carbamazepine-10, 11-epoxideF Pisani, A Fazio, G Oteri, et al.
Clinical Pharmacology and Therapeutics|July 1, 1989
Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beingsM L Dahl-Puustinen, A Lidén, C Alm, et al.
Pharmacopsychiatry|December 17, 2003
Individualized medicine - implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disordersJ Kirchheiner, L Bertilsson, H Bruus, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 22, 2001
Moving toward genetic profiling in patient care: the scope and rationale of pharmacogenetic/ecogenetic investigationG Alvan, L Bertilsson, M L Dahl, et al.
Pharmacogenetics|January 14, 2000
Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genesP Dalén, M L Dahl, M Eichelbaum, et al.
Pageof 27

Showing results (151-160 of 263) with videos related to

Sort By:
Pageof 27
Pharmacology & Toxicology|February 1, 1991
Stereoselective efflux of (E)-10-hydroxynortriptyline enantiomers from the cerebrospinal fluid of depressed patientsL Bertilsson, K Otani, M L Dahl, et al.
Biological Psychiatry|September 24, 1999
Locus coeruleus neuronal activity and noradrenaline availability in the frontal cortex of rats chronically treated with imipramine: effect of alpha 2-adrenoceptor blockadeL Linnér, L Arborelius, G G Nomikos, et al.
Therapeutic Drug Monitoring|May 22, 2001
Determination of exogenous melatonin and its 6-hydroxy metabolite in human plasma by liquid chromatography-mass spectrometryS Härtter, S Morita, K Bodin, et al.
Archives of General Psychiatry|July 1, 1980
Cortisol in the CSF of depressed and suicidal patientsL Träskman, G Tybring, M Asberg, et al.
Therapeutic Drug Monitoring|January 1, 1988
Single-dose kinetics of an enteric-coated formulation of carbamazepine-10,11-epoxide, an active metabolite of carbamazepineE Spina, T Tomson, J O Svensson, et al.
British Journal of Clinical Pharmacology|May 1, 1988
Effect of valpromide on the pharmacokinetics of carbamazepine-10, 11-epoxideF Pisani, A Fazio, G Oteri, et al.
Clinical Pharmacology and Therapeutics|July 1, 1989
Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beingsM L Dahl-Puustinen, A Lidén, C Alm, et al.
Pharmacopsychiatry|December 17, 2003
Individualized medicine - implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disordersJ Kirchheiner, L Bertilsson, H Bruus, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 22, 2001
Moving toward genetic profiling in patient care: the scope and rationale of pharmacogenetic/ecogenetic investigationG Alvan, L Bertilsson, M L Dahl, et al.
Pharmacogenetics|January 14, 2000
Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genesP Dalén, M L Dahl, M Eichelbaum, et al.
Pageof 27